CMC Pharmaceuticals Awarded SBIR Grant For Concentrated Atropine Formulation
Date: April 6, 2022
Posted by:

CMC Pharmaceuticals Awarded SBIR Grant For Concentrated Atropine Formulation

Solon, OH: CMC Pharmaceuticals has been awarded a Small Business Innovation (SBIR) grant from U.S. Special Operations Command (SOCOM). The Phase I SBIR award will fund the formulation and analytical development of a concentrated Atropine Sulfate Drug Product. The application of this new formulation aims to aid the military in treating organophosphate poisoning in service members. 

“CMC Pharma has significant experience developing injectable atropine and related formulations for medical countermeasures,” said Dr. Radomsky, Principal Investigator and President of CMC Pharma. “The team is honored to have been awarded the SBIR and we are thrilled to support the Department of Defense and SOCOM by developing pharmaceutical products to protect our service members.”

The objective of the formulation is to reduce the logistical burden in treating severe cases of organophosphate poisoning. Upon development of the concentrated atropine sulfate formulation, CMC Pharma plans to execute future studies to support FDA approval of the drug product and secure the appropriate supply chain.  CMC Pharma aims to commercialize the drug product for inclusion in the national strategic stockpile.

In addition to military uses for treating organophosphate poisoning of service members, atropine sulfate is indicated for the temporary blockade of severe or life threatening muscarinic effects, e.g., as an antisialagogue, an antivagal agent, an antidote for organophosphorus or muscarinic mushroom poisoning, and to treat bradyasystolic cardiac arrest.  CMC Pharma intends to seek approval for all relevant military and civilian uses.   

For more information about CMC Pharma’s team and drug product formulation expertise, visit

About CMC Pharmaceuticals:

CMC Pharmaceuticals is a leading provider of drug product development services and manufacturing support to the pharmaceutical and biotechnology industries. CMC Pharmaceuticals delivers its specialized scientific expertise and services including pre-formulation, formulation development, analytical development, cGMP lab services, stability and compatibility studies, manufacturing process development, and consulting services to clients globally. CMC Pharmaceuticals offers decades of specialized scientific experience in the development and manufacture of a wide range of drug product types including sterile, solid, semi-solid/liquid, topical, long-acting, controlled release, and other complex dosage forms.


Jared Heimovitz
CMC Pharmaceuticals

Jared Heimovitz